Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
GRENOBLE, France, July 1, 2014 /PRNewswire/ -- ImmunID, a French Immune Molecular Diagnostics company, today embarked on an agreement with the Singapore Immunology Network (SIgN), a research institute under the Agency of Science, Technology and Research (A*STAR), Singapore. Under the agreement, ImmunID will use its proprietary ImmunTraCkeR® and ImmunIG® tests to evaluate T and B immune repertoire diversity in the blood of patients enrolled in a SIgN-led clinical trial.
"New approaches to evaluate such as the ones developed by ImmunID, broaden our scope of exploration of the human immune system. We can now get a more comprehensive understanding of it, using parameters such as immune repertoire diversity, which were neglected in the past," stated Dr Anis Larbi, Principal Investigator of the program, at SIgN. "We are looking forward to collaborating with ImmunID to study how immune competence impacts health outcomes," he added.
Acting Executive Director of SIgN, Associate Professor Laurent Renia, said, "SIgN welcomes such collaborations as there are synergies in leveraging on each partner's expertise. The human immune system is complex and has to be translated for scientists to interpret the immune functions. ImmunID's competency in producing reliable immune data therefore complements the immunology studies done at SIgN."
"We are very excited to cooperate with SIgN, one of the leading institutes pioneering basic and applied immunology research in infections and inflammatory conditions, and look forward to the joint exploration of immune competence in a new strategic indication," said Dr Bernhard Sixt, Chairman and CEO of ImmunID. "We hope to create further insight into variations of the immune system's strength overtime and among individuals in order to help physicians adapt the therapeutic strategy and to lead to better patient outcomes," he added.
The project will last for 2 years and include 180 subjects. The indication and therapeutic intervention studied in SIgN's clinical trial were not disclosed.
About the Singapore Immunology Network (SIgN)
The Singapore Immunology Network (SIgN), officially inaugurated on 15 January 2008, is a research consortium under the Agency for Science, Technology and Research (A*STAR)'s Biomedical Research Council. The mandate of SIgN is to advance human immunology research and participate in international efforts to combat major health problems. Since its launch, SIgN has grown rapidly and currently includes 250 scientists from 26 different countries around the world working under 28 renowned principal investigators. At SIgN, researchers investigate immunity during infection and various inflammatory conditions including cancer and are supported by cutting edge technological research platforms and core services.
Through this, SIgN aims to build a strong platform in basic human immunology research for better translation of research findings into clinical applications. SIgN also sets out to establish productive links with local and international institutions, and encourage the exchange of ideas and expertise between academic, industrial and clinical partners and thus contribute to a vibrant research environment in Singapore.
For more information about SIgN, please visit www.sign.a-star.edu.sg
ImmunID has been a pioneer in the immune molecular diagnostic field since 2005. Its two clinical products ImmunTraCkeR® and ImmunIg® evaluate T and B cell repertoire diversity, respectively. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic for all immunotherapies and setting the general immune molecular diagnostics standard globally. ImmunID collaborates with leading clinical research centers and biopharmaceutical companies worldwide to further validate ImmunTraCkeR® as an immune companion diagnostic test for new immunotherapies and to widen clinical utility of its products. The company is ISO9001 certified and runs an ISO13485 accredited production and R&D facility in the MINATEC high-tech campus in Grenoble, France. In addition, ImmunID has applied for CAP accreditation / CLIA certification of its central lab to be able to provide ImmunTraCkeR® routinely to clinical patients in the United States.
For further information, please contact ImmunID:
Chairman and CEO
Phone: +33 438 785 770
©2012 PR Newswire. All Rights Reserved.